Gyre Therapeutics (GYRE) Q3 2026 earnings review
Gyre's lead lung drug grows, but merger costs erase profit
Gyre Therapeutics, a drugmaker selling lung medicines in China to fund cancer research, grew its main product but slipped into an operating loss. Sales of its flagship lung drug ETUARY climbed 13% from a year ago to $31 million, making up for an expired research partnership and state price cuts on two newer drugs. However, chief executive Ying Luo absorbed a first full quarter of costs from the May purchase of Cullgen, which pushed overhead and research spending above sales.
| Commercial drug sales (excluding expired partnership) | $32.5M +6.9% from a year ago by our math |
|---|---|
| Total revenue | $32.9M +0.7% from a year ago |
| Profit excluding one-offs | $0.4M $3.9M a year ago (-91%) |
| Full-year revenue outlook | Unchanged $100.5–111.0M (middle of the range: $105.8M) |
⚖️ Verdict: 🔴 Bearish
The story got worse because adding Cullgen's drug pipeline raised running costs enough to wipe out the profit from China drug sales. Clinical timelines also slipped, as the company pushed human trial applications for two cancer and autoimmune drugs from early 2027 to mid-2027 and flagged patient dropouts in a late-stage lung study. The bright spot: Chinese regulators finished inspecting the factories for lead liver drug F351, keeping a commercial launch on track for the first half of 2027.
The question now is whether the unchanged full-year sales outlook reflects management caution or an upcoming fourth-quarter drop in China drug orders. With $86 million booked in the first nine months, by our math the middle of the full-year plan leaves $19 million for the fourth quarter, down 48% from a year ago. Fourth-quarter results and China's regulatory decision on F351, expected by early 2027, will settle both points.
🐂 Bull Case
ETUARY Carries Sales While Newer Drugs Shrink
Gyre relies on ETUARY, its flagship medicine for idiopathic pulmonary fibrosis (a scarring lung disease) in China, to pay for drug research. Total revenue rose 0.7% from a year ago to $32.9 million because Astellas Pharma ended a research partnership in March 2026, reducing collaboration revenue by $1.6 million.
Stripping out that expired partnership, sales of the company's three commercial drugs grew 6.9% to $32.5 million by our math. Focused marketing lifted ETUARY volume, pushing the drug's sales up 13.4% to $31.4 million. That growth covered declines in two newer medicines and kept overall revenue moving up from the second quarter.
What to watch: fourth-quarter ETUARY sales when full-year results arrive in March. Holding above $30 million would show the core lung franchise can fund research on its own.
Lead Liver Drug Passed Its Factory Inspection
F351 (hydronidone) is Gyre's next big commercial bet, an experimental pill for liver scarring caused by chronic hepatitis B. Chinese regulators accepted its application for priority review in May 2026.
During the third quarter, China's National Medical Products Administration (NMPA, the country's drug regulator) completed on-site inspections of the manufacturing plants and clinical centers for F351. Clearing the site checks keeps the review on track for a decision by early 2027 and a commercial launch in the first half of 2027, chief executive Ying Luo said.
What to watch: the regulatory decision from China's NMPA, due between late 2026 and the first quarter of 2027. Approval lets the 370-person sales team sell a second major fibrosis drug.
🐻 Bear Case
Higher Overhead and Research Costs Erased Profit
Chief executive Ying Luo said the quarter represents "our first full quarter incorporating Cullgen's operations within Gyre Therapeutics" and will "demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China". Gyre bought Cullgen in May 2026 to develop protein degraders, drugs that destroy disease-causing proteins.
- Operating margin: -4.6%, down 9.2 percentage points from a year ago
- General and administrative expense (overhead): 27.1% of revenue, up 7.4 percentage points
- Research and development expense: 25.8% of revenue, up 2.0 percentage points
- Profit excluding one-offs: $0.4 million, down 90.9% from $3.9 million a year ago
The numbers test Luo's claim that China sales cover research expenses. Overhead jumped 39% to $8.9 million on restructuring payroll and legal fees, pushing the drugmaker into a $1.5 million operating loss even as sales costs fell 1.2 percentage points of revenue.
What to watch: quarterly general and administrative spending in the fourth-quarter report. A drop back toward $7 million would show the jump was temporary merger cleanup rather than permanent overhead.
State Bulk-Buying Cut Newer Drug Sales
Gyre launched two generic drugs in China in 2025 to reduce its reliance on ETUARY: Etorel for lung scarring and Contiva for low blood platelet counts. Both medicines ran into government price cuts "due to the implementation of China’s national centralized procurement program", the state bulk-buying system that lowers hospital drug prices.
Etorel sales fell 33.3% from a year ago to $1.0 million, while higher Etorel production costs pushed total cost of revenues up 20%. Contiva revenue dropped 91.7% to $0.1 million, leaving ETUARY at 95% of total revenue by our math.
What to watch: gross margin in the fourth quarter after dipping 0.9 percentage points to 94.1% this quarter. Further drops would mean low-priced Etorel volumes are dragging down manufacturing profitability.
Cancer Drug Filings Slipped and Dropouts Hit Trial
Clinical timelines across both the newly acquired cancer pipeline and the older lung programs moved back this quarter. Three months ago, Gyre planned to file Investigational New Drug (IND) applications, the regulatory request to start human testing, in the first quarter of 2027 for its two lead dual-degrader drugs, CG923308 for solid tumors and CG620953 for autoimmune diseases.
The company now expects those filings and Phase 1 trial starts around mid-2027. Separately, a 272-patient Phase 3 study of pirfenidone for pneumoconiosis (coal-worker lung disease) was supposed to finish in the third quarter, but Gyre is now evaluating enrolling more patients "to replace patients that have dropped out of the study".
What to watch: whether Gyre re-opens enrollment for the pneumoconiosis trial in early 2027. Adding new patients to a 52-week study would push final results out by another year.
💲 Other KPIs
Total cash and bank deposits fell 14.9% from $116.1 million at the end of 2025, and declined by $4.4 million from $103.2 million at the end of June by our math. Most of the year-to-date spend went toward a $4.8 million regulatory milestone payment and $6.9 million in merger transaction fees in the first half.
Share count rose 17.0% from 90.9 million a year ago, and climbed 5.6% from 100.6 million in the second quarter. The drugmaker issued shares in May 2026 to complete its all-stock purchase of Cullgen, diluting existing stockholders.
Stockpiles of raw materials and finished medicines rose 20.1% from $10.2 million at the end of 2025, and grew 6.9% from $11.4 million in the second quarter by our math. Inventory expanded much faster than the 0.7% increase in quarterly revenue as the Beijing plant prepares for wider distribution.
🔮 Guidance
Unchanged. The full-year plan still calls for $105.75 million at the middle of the range, down 9.3% from $116.6 million reported in 2025. With $86.5 million booked in the first nine months, by our math the outlook leaves $14.0 million to $24.5 million for the fourth quarter ($19.3 million at the middle, down 48.2% from a year ago). That implies a steep fourth-quarter drop or a very cautious target.
❓ Key Questions
Why does the full-year outlook point to a fourth-quarter drop?
With $86.5 million in nine-month revenue, the unchanged $100.5–111.0 million full-year plan leaves $19.3 million at the middle of the range for the fourth quarter by our math, down 41% from the third quarter. Did management leave the range untouched out of caution, or will distributor orders drop?
Where is the U.S. trial filing for F351 in liver disease?
In the first quarter of 2026, Gyre planned to file a U.S. application by the end of 2026 to start a Phase 2 trial of F351 in metabolic liver fibrosis (MASH). This release says the team is still analyzing Chinese Phase 3 and preclinical data with no timeline.
How many patients dropped out of the coal-worker lung study?
The 272-patient Phase 3 trial of pirfenidone in pneumoconiosis finished enrolling in 2025 and was slated to complete in the third quarter of 2026. Evaluating replacement enrollment now suggests high dropout rates that could threaten the trial's statistical power and delay results by a year.
When will overhead costs stop rising after the Cullgen merger?
General and administrative expenses climbed 39% from a year ago to $8.9 million in the first full quarter after the Cullgen merger closed. How much of the $0.9 million restructuring payroll and $1.1 million professional fee increase will repeat in 2027?